{'fraction_non_alphanumeric': 0.03136882129277566, 'fraction_numerical': 0.004752851711026616, 'mean_word_length': 5.230769230769231, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Verve tackles heart disease

Verve Therapeutics has launched with $58.5 million in funding to pursue a lofty goal: ridding the world of the leading cause of death, coronary heart disease. The Cambridge, Massachusetts–based biotech firm plans to use gene-editing tools to develop drugs that permanently address the underlying causes of heart disease. Currently, people with heart disease take daily cholesterol-lowering pills. But they don’t help everyone: in the US alone, someone has a heart attack every 40 seconds, according to the American Heart Association. Verve wants to change that, says founder and CEO Sekar Kathiresan, a renowned cardiologist who will leave his academic posts at Massachusetts General Hospital, the Broad Institute, and Harvard Medical School to lead the firm. “Imagine an injection administered once a life that safely lowers cholesterol—lifelong—and confers enduring protection against heart attack in adults.” That theoretical once-and-done injection will be a CRISPR-based therapeutic that can turn off specific genes...